Yingqian Zhu1, Qingqing Li1, Hua Jiang1. 1. Department of Geriatrics, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Abstract
The increasing prevalence of cardiovascular diseases cannot adequately be explained by traditional risk factors. Recently, accumulating evidence has suggested that gut microbiota-derived numerous metabolites are contributors to atherosclerotic events. Among them, the role of trimethylamine N-oxide (TMAO) in promoting atherosclerosis has gained attention. TMAO is reported to exert the proatherogenic effects by impacting on the traditional risk factors of atherosclerosis and is associated with high risk of cardiovascular events. Besides that, TMAO is involved in the complex pathological processes of atherosclerotic lesion formation, such as endothelial dysfunction, platelet activation and thrombus generation. In light of these promising findings, TMAO may serve as a potential target for atherosclerosis prevention and treatment, which is conceptually novel, when compared with existing traditional treatments. It is likely that regulating TMAO production and associated gut microbiota may become a promising strategy for the anti-atherosclerosis therapy.
The increasing prevalence of cardiovascular diseases cannot adequately be explained by traditional risk factors. Recently, accumulating evidence has suggested that gut microbiota-derived numerous metabolites are contributors to n class="Disease">atherosclerotic events. Among them, the role of trimethylamine N-oxide (TMAO) in promoting atherosclerosis has gained attention. TMAO is reported to exert the proatherogenic effects by impacting on the traditional risk factors of atherosclerosis and is associated with high risk of cardiovascular events. Besides that, TMAO is involved in the complex pathological processes of atherosclerotic lesion formation, such as endothelial dysfunction, platelet activation and thrombus generation. In light of these promising findings, TMAO may serve as a potential target for atherosclerosis prevention and treatment, which is conceptually novel, when compared with existing traditional treatments. It is likely that regulating TMAO production and associated gut microbiota may become a promising strategy for the anti-atherosclerosis therapy.
Authors: Sepiso K Masenga; Benson Hamooya; Joy Hangoma; Valerie Hayumbu; Lale A Ertuglu; Jeanne Ishimwe; Sharla Rahman; Mohammad Saleem; Cheryl L Laffer; Fernando Elijovich; Annet Kirabo Journal: J Hum Hypertens Date: 2022-04-25 Impact factor: 3.012
Authors: Daniel A Schupack; Ruben A T Mars; Dayne H Voelker; Jithma P Abeykoon; Purna C Kashyap Journal: Nat Rev Gastroenterol Hepatol Date: 2021-08-27 Impact factor: 46.802
Authors: Thomas Roder; Daniel Wüthrich; Cornelia Bär; Zahra Sattari; Ueli von Ah; Francesca Ronchi; Andrew J Macpherson; Stephanie C Ganal-Vonarburg; Rémy Bruggmann; Guy Vergères Journal: Microorganisms Date: 2020-06-27